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Next generation maleimides enable the controlled
assembly of antibody–drug conjugates via native
disulﬁde bond bridging†
Felix F. Schumacher,‡a João P. M. Nunes,‡a Antoine Maruani,a Vijay Chudasama,a
Mark E. B. Smith,a Kerry A. Chester,b James R. Baker*a and Stephen Caddick*a
The advent of Adcetris™ and Kadcyla™, two recently FDA-approved antibody–drug conjugates (ADCs), in
the clinic has had a major impact on the treatment of lymphoma and breast cancer patients, respectively,
worldwide. Despite these successes many new ADCs fail at various stages of development, often due to
shortcomings in the methods used for their assembly. To address this problem we have developed next
generation maleimides (NGMs), which speciﬁcally re-bridge reduced interchain disulﬁde bonds and allow
the eﬃcient conjugation of small molecules to antibodies, without the need for engineering of the target
antibody. The method is site-speciﬁc and generates near homogeneous products in good yields. More-
over, adjustment of the reaction conditions allows control of the conjugation in terms of stoichiometry
(drug-loading) and site selectivity. Using this method we prepared a series of ADCs from trastuzumab and
doxorubicin (DOX) with a controlled drug-to-antibody ratio (DAR) of 1, 2, 3 and 4. All of these constructs
were fully active by ELISA and had more than 90% of re-bridged disulﬁde bonds by CE-SDS when com-
pared to clinical grade antibody. Furthermore, digest experiments of the DAR 2 material revealed that
almost all of the drug had been targeted to the Fab arms of the antibody. Thus, NGMs oﬀer a ﬂexible and
simple platform for the controlled assembly of ADCs from an antibody.
Introduction
From all drug classes currently under development, antibody–
drug conjugates (ADCs) come closest to Paul Ehrlich’s late 19th
century vision of the perfect medicine, the “magic bullet”.1
The specific binding capability of an antibody enables delivery
of an attached cytotoxic drug (payload) to a specific site, which
in principle restricts undesirable oﬀ-site toxicity eﬀects.2
Despite being a relatively simple hypothesis, the development
of ADCs is marked with many failures.3 Only three molecules
of this drug class have received regulatory approval to date,
one of which has been voluntarily withdrawn from the market
due to a lack of eﬃcacy.3
One of the major issues for ADCs is the limited amount of
cytotoxic compound that ultimately reaches the tumor.4 As a
consequence ADCs typically incorporate very potent toxins,
such as tubulin inhibitors monomethyl auristatins E5–8 and
F9,10 or the novel DNA intercalators pyrrolobenzodiazepines.11
The nature of these toxins necessitates the use of robust lin-
kages to the antibody, which is inherently reliant on the under-
lying conjugation strategy. Of particular importance is the
selectivity of the conjugation method employed – non-selective
methods will lead to a heterogeneous mixture of ADC species
which12 will have diﬀerent binding activities, potencies, thera-
peutic indexes, clearance rates and other properties.13–16
Homogeneous ADCs are also desirable from a production
point of view, as heterogeneity places a large burden on purifi-
cation, analytics and quality control17 to ensure patient safety,
which may become an important consideration for regulatory
stakeholders.18
Developing conjugation methods to deliver homogeneous
products can in principle be achieved if the reaction is selec-
tive for particular conjugation sites and progresses to com-
pletion. In addition, it is important that the conjugation
linkage is stable for storage and use in vivo. The conjugation
methods currently used to assemble ADCs are sub-optimal.
Kadcyla™ is produced via lysine conjugation,19,20 which, with
as many as 20 solvent accessible lysines in a typical antibody,
is not site-specific and thus cannot be allowed to go to
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completion. An alternative strategy used for the synthesis of
Adcetris™ relies on partial reduction of interchain disulfide
bonds followed by alkylation.6,21 In this case, the number of
conjugation sites diﬀers due to the non-selective nature of the
reduction step, thus resulting in a variety of drug-to-antibody
(DAR) conjugation ratios. Furthermore the loss of the disulfide
bonds introduces stability issues in vivo, as does the use of tra-
ditional maleimide reagents for conjugation.22–25
A number of innovative solutions have been developed to
enable the synthesis of highly homogeneous products. “Thio-
mabs”, which yield ADCs with a DAR close to 2, are based on
the insertion of additional free cysteines into the amino acid
sequence of the antibody.15,24 In a similar fashion, the
expression of antibodies containing non-natural amino acids
that can be targeted to install small molecules via “click chem-
istry” has been established.26 Another alternative involves
insertion of small amino acid sequences into the antibody,
which can then be used for conjugation using enzymatic
methods.27 Common to all of these methods is their depen-
dence on protein-engineering to insert additional reactive
groups for conjugation. Whilst technically feasible this adds
an additional layer of complexity to the production process of
ADCs, requiring detailed optimisation for determining suit-
able insertion sites and introducing potential challenges for
scale-up and reproducibility.
To avoid these issues we have developed reagents (next
generation maleimides, NGMs) for site-selective conjugation
in a controlled manner, using a feature native to all antibody
sub-classes: their interchain disulfide bonds. NGMs are a new
class of maleimides, which are substituted in the 3- and
4-position with good leaving groups enabling reaction with
two nucleophilic thiol groups such as the two cysteines of a
reduced cystine.28 This chemical process inserts a 2-carbon
bridge into a disulfide bond keeping this structural feature
intact whilst functionalizing the protein of interest. The reac-
tion is fast, eﬃcient, high yielding and generates stable pro-
ducts that retain their full biological activity.29 Therefore,
NGMs fulfill the theoretical criteria for the synthesis of homo-
geneous conjugation products. Herein we show how this class
of compound can be used in the production of near homo-
geneous ADCs without the need for antibody-engineering
(Fig. 1a).
Results and discussion
Bridging the interchain disulfide bonds of trastuzumab
To explore the suitability of NGMs in the context of the prepa-
ration of ADCs we first needed to establish if eﬃcient re-brid-
ging of the multiple disulfide bonds of a full-length antibody
was feasible. We selected clinically validated drug trastuzumab
(Herceptin™), a monoclonal IgG1 antibody that targets the
internalising HER2 receptor, which is in wide use for the treat-
ment of HER2 positive breast cancer.30 It is also the antibody
component of ADC trastuzumab emtansine (Kadcyla™).19
Initially, all four solvent accessible disulfide bonds of trastuzu-
mab were reduced in PBS buﬀer with a large excess of reducing
agent (20 eq. TCEP, Fig. 1b, lane 3) followed by the addition of
dibromomaleimide 1 (25 eq.) without any payload attached.
Our initial results were promising as SDS-PAGE revealed for-
mation of fully bridged antibody (Fig. 1b, lane 4), however, sig-
nificant fragmentation was also observed. It should be noted
that this was visible only when samples were heat-treated
before the run to ensure full dissociation of heavy and light
chains (HCs and LCs) not connected by an intact interchain
bridge. No free thiol group was detected by an Ellman’s test in
the purified product, indicating that NGMs do react very
eﬃciently. However, the method clearly needed further optimi-
sation. To this end, a screen of conditions was carried out,
Fig. 1 Bridging of native antibody disulﬁde bonds with NGMs. (a)
Sequential and in situ functionalisation of antibodies with NGMs (b)
Initial sequential modiﬁcation. (M) Molecular marker. (1) Untreated anti-
body. (2) Reduced antibody. (3) Antibody reduced in the presence of
DMF. (4) Reduction with 20 eq. TCEP, followed by addition of 25 eq.
dibromomaleimide. (c) Optimized sequential modiﬁcation. (M) Molecular
marker. (1) Untreated antibody. (2) Reduced antibody. (3) Antibody
reduced in the presence of DMF. (4) Reduction with 6 eq. TCEP in pH
8.0 for 2 h at 37 °C followed by addition of 5 eq. dibromomaleimide in
10% ﬁnal DMF for 1 h. (d) Selenol-based in situ modiﬁcation. (M) Mole-
cular marker. (1) Untreated antibody. (2) Bridging with 10 eq. benzenese-
lenol and 20 eq. dithiophenolmaleimide in pH 8.0, 15% DMF on ice for
2 h. (e) TCEP-based in situ modiﬁcation. (M) Molecular marker. (3)
Untreated antibody. (4) Bridging with 7 eq. TCEP and 7 eq. dithiophenol-
maleimide in pH 8.0, 10% DMF at 37 °C for 2 h.
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focusing on the following parameters: pH, time, temperature,
organic solvent and concentration (Fig. S1, ESI†). Combining
the findings of these experiments in an improved re-bridging
protocol yielded promising results (Fig. 1c).
Using a revised protocol, the dissociation of the peptide
chains was greatly reduced leading to the isolation of two pro-
ducts, completely re-bridged antibody (i.e. LHHL) and half-
antibody (i.e. HL).
We speculate that the formation of this second, half-anti-
body species can be explained by formation of intrachain
bridges. This is possible because the cysteines that form the
two disulfide bonds connecting the HCs in the so-called hinge
region are separated by only two amino acids. When comple-
tely reduced and then re-bridged these can either form the
original interchain connections giving full antibody, or make
intrachain bridges to produce half-antibody by prohibiting
covalent connection of the HCs permanently.
In order to overcome the intrinsic challenge associated with
improving hinge region connectivity, we explored the use of an
in situ method, which we reasoned would avoid disulfide bond
shuﬄing by facilitating immediate re-connection of any
opened cystines.28 After some experimentation we discovered
that using dithiophenolmaleimide 2 in tandem with either
TCEP or benzeneselenol (Fig. S2, ESI†) could help mitigate
fragment formation as confirmed by SDS-PAGE (Fig. 1d and e).
Most notably, we found that in situ modification of trastuzu-
mab with the selenol reagent was best performed at 0–4 °C
whilst the ideal reaction temperature when using TCEP was
37 °C.
Synthesis of NGM-doxorubicin
We then explored the possibility of using NGMs for conju-
gation of full antibodies with cytotoxic drugs. We selected anti-
cancer drug doxorubicin (DOX) as a warhead, given its prior
use as a model payload in ADCs and its convenient UV-vis
absorption profile that would facilitate DAR analysis.12,31,32 We
prepared NGM-DOX compounds 3 and 5, bearing a C6 alkyl
chain. Compound 5 also possesses the valine-citrulline linker
for drug release by lysosomal cathepsin B cleavage, which is
used in several ADCs.6,15,31,33–35 Compound 4 was synthesized
to allow evaluation of maleamic acid conjugates.36 The prepa-
ration of M-DOX 6 enabled comparison with existing techno-
logies (Fig. 2).
The preparation of these compounds started with conden-
sation of 3,4-dibromomaleic anhydride and the chosen amine
in acetic acid in accordance with the literature.37 This was fol-
lowed by addition of thiophenol to aﬀord precursors 12 and 13
under eﬃcient and mild conditions.28 DOX was attached using
HBTU promoted amide bond formation to aﬀord NGM-DOX
3 and 4.
Fig. 2 Synthesis of NGM-DOX 3–5 and M-DOX 6.
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It is notable that whilst dibromomaleimides can be prone
to side reactions in couplings with amines, reaction was facile
and high yielding for dithiomaleimides. Since dithiophenol-
maleimides are just as eﬀective as dibromomaleimides for
cysteine conjugation and allow for in situ methods, we focused
exclusively on NGM-DOX compounds 3–5 herein. M-DOX 6
was also prepared by the described methods. The valine-
citrulline p-aminobenzyl alcohol linker (Val-Cit-PABOH) was
synthesised as reported31 and coupled to compound 12 in
high yield via HBTU promoted amide bond formation.
This was followed by reaction with p-nitrophenyl chloro-
formate and subsequent addition of DOX to aﬀord NGM-DOX
5 (Fig. 2).
Assembly of trastuzumab–doxorubicin conjugates with NGMs
With NGMs 3–5 in hand we attempted to prepare ADCs with a
DAR of 4 by targeting all 4 solvent accessible interchain disul-
fides in trastuzumab, initially via the sequential protocol
(Fig. 3a) as described above. Despite the propensity of this pro-
tocol to generate some half-antibody, it allowed for direct com-
parison with alternative contemporary methods of conjugation
(e.g. with compound 6). The sequential method using only a
slight excess of NGM-DOX reagents 3, 4 and 5 (5 eq., 1.25 eq.
per disulfide bond) provided DARs measured by UV-vis of 3.8,
3.0 and 3.5, respectively (Fig. S3, ESI†), with very high yields of
the conjugates obtained after purification (Fig. 3b). Complete
cysteine selectivity was confirmed by virtue of the following
observations: no conjugation observed between the NGMs and
unreduced trastuzumab (Fig. 3c, lane 9); the absence of sul-
phydryls following conjugation as determined via Ellman’s
analysis (Table S1, ESI†); and no further reaction observed
with increased equivalents of NGMs.
The NGM-DOX reagents demonstrated less fragmentation
(Fig. 3c, lanes 5, 6 and 7) compared to the use of simple male-
imide compound 6, which aﬀorded all possible fragments
(Fig. 3c, lane 3). However, consistent with our expectations, we
observed formation of half-antibody (HL) in all cases of conju-
gation with NGMs 3–5. Nonetheless, ADCs prepared with
NGM-DOX 3–5 did still retain full binding activity to the HER2
antigen, as determined by ELISA (Fig. 3d).
We next explored the use of in situ protocols to avoid the
formation of half antibody using NGMs 3–5 and successfully
achieved moderate to good DAR values (Fig. S4, ESI†) in high
yields (Fig. 4b) and with negligible free sulphydryl groups in
the product (Table S2, ESI†). The quantity of half-antibody was
dramatically reduced, as indicated by SDS-PAGE and this was
confirmed by quantitative capillary gel electrophoresis
(CE-SDS) analysis (Fig. 4c and d). The use of NGMs 3 and 5 led
to decreased levels of half-antibody and with good DARs. The
use of NGM-DOX 4 under in situ conditions was optimal, gen-
erating conjugates with only minor by-products resulting from
fragmentation. This shows that the in situ method is capable
of aﬀording a full antibody ADC with high selectivity and in
good yields. As anticipated, ADCs prepared by the in situ proto-
col displayed excellent retention of binding activity to HER2
(Fig. 4e).
Fig. 3 Bridging of native antibody disulﬁde bonds via optimised sequential method. (a) General outline of conjugation with NGM-DOX 3–5, com-
pared to conjugation with M-DOX 6. (b) Isolated yields and DAR from conjugation reactions. (c) Analysis by SDS-PAGE: (M) Molecular marker. (1)
Untreated antibody. (2) Reduced antibody with 2 eq. TCEP. (3) Conjugation with 5 eq. M-DOX 6. (4) Reduced antibody with 6 eq. TCEP. (5) Conju-
gation with 5 eq. NGM-DOX 3. (6) Conjugation with 5 eq. NGM-DOX 4. (7) Conjugation with 5 eq. NGM-DOX 5. (8) Reduced antibody with 6 eq.
TCEP in the presence of DMF 10% without NGM. (9) Unreduced antibody with DMF 10% and NGM-DOX 3 (DAR 0). (d) Binding activity of trastuzumab
ADCs with NGM-DOX 3–5 to HER2 compared to unmodiﬁed trastuzumab.
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NGM-DOX 4 consistently aﬀorded the lowest DARs, whether
generated using the sequential (3.0) or in situ (1.8) protocols,
and we suspected that this might be a consequence of hydro-
lysis of the conjugate. NGM-DOX 4 was designed to undergo
rapid hydrolysis to generate maleamic acid bridges following
conjugation and this was verified by SDS-PAGE (Fig. S5,
ESI†).36 To explore this further, we modified trastuzumab Fab
with NGM-DOX 4 and confirmed full hydrolysis of maleimide
to maleamic acid using mass spectrometry (Fig. S6, ESI†). Sig-
nificantly, mass spectrometry also revealed partial hydrolysis
of the acetal moiety in DOX (Table S3, ESI†). The instability of
DOX has been documented38 and we have previously reported
similar observations for another N-aryl maleamic acid DOX
construct.39 Thus, we believe the lower DAR observed with
NGM-DOX 4 is more likely to be due to DOX acetal hydrolysis
over the extended conjugation time of 2 h rather than a limit-
ation of the conjugation chemistry.
Controlling drug loading and localization
To avoid problems based on the model payload and to assess
the true potential of NGMs in the context of ADC synthesis we
decided to examine an alternative approach in which the brid-
ging reaction and the drug-conjugation step could be carried
out separately. To this end, we prepared N-alkyne-
dithiophenolmaleimide 15,40 which would be inserted into the
trastuzumab disulfide bonds to provide a bioconjugate ready
for further elaboration. We also prepared a DOX-azide species
16 containing a polyethylene glycol (PEG) chain that we envi-
saged could lead to conjugation via a copper catalysed 3 + 2
cycloaddition (Fig. 5a).41
Modification of the target antibody with compound 15 via
TCEP and benzeneselenol protocols proceeded as expected
(Fig. S7, ESI†) and yielded the desired intermediate in more
than 80% yield (Fig. 5c). Copper-catalysed Huisgen 1,3-dipolar
cycloaddition (click reaction) was carried out in the presence
of 3[tris(3-hydroxypropyltriazolylmethyl) amine] (THPTA) and
aminoguanidine hydrochloride using a seven fold excess of 16
per disulfide bond, which had negligible impact on antibody
fragmentation (Fig. S7, ESI†).
The products were purified by size exclusion chromato-
graphy (SEC) and we isolated ADCs in 52–69% yield (Fig. 5c).
We observed that TCEP-based protocols gave DARs between 3
and 4, whilst methods employing benzeneselenol yielded
DARs between 1 and 2 (Fig. S8, ESI†). We explored this obser-
vation further in an attempt to develop protocols that would
deliver a series of trastuzumab–DOX conjugates with distinct
DARs. Careful variation of the reaction conditions, including
repeated additions of benzeneselenol, adjusting TCEP
stoichiometry and moderating reaction times enabled us to
develop protocols for the synthesis of ADCs with DARs of 1.1,
2, 3.1 and 4 (Fig. 5b and c). Furthermore, all molecules iso-
lated contained more than 90% of the connected interchain
bridges, at least 74% of intact antibody (Fig. 5d), and retained
full binding activity as shown by ELISA (Fig. 5e).
The 4 solvent accessible cystines in IgG1 antibodies can be
divided into 2 groups: 2 of them in the hinge region and 2 in
the switch/Fab region. The fact that the selenol-based in situ
protocol did not yield ADCs with a DAR higher than 2
prompted us to explore the possibility that the selenol-based
protocol was reacting specifically with the Fab arms.
Fig. 4 Bridging of native antibody disulﬁde bonds via in situ method. (a) General outline of conjugation with NGM-DOX 3–5. (b) Isolated yields and
DAR from conjugation reactions. (c) Analysis by SDS-PAGE: (M) Molecular marker. (1) Untreated antibody. (2) Conjugation with 5 eq. NGM-DOX 3. (3)
Conjugation with 5 eq. NGM-DOX 4. (4) Conjugation with 5 eq. NGM-DOX 5. (d) CGE of conjugation with NGM-DOX 4 by diﬀerent methods; peak
area given as percentage of total peak area: (1) sequential method with 5 eq. of NGM-DOX 4. (2) in situ method with 5 eq. of NGM-DOX 4.
(e) Binding activity of trastuzumab ADCs with NGM-DOX 3–5 to HER2 compared to unmodiﬁed trastuzumab.
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Proteolytic digestion of the trastuzumab–DOX DAR 2 conju-
gate derived from the selenol protocol allowed us to isolate the
corresponding Fab fragments (Fig. 5f) with a DAR of 0.79
(Fig. S9, ESI†). As direct readout from this process would be
misleading due to issues of DOX stability under the reaction
conditions, we required an appropriate control/correction
factor. To this end, we synthesized a Fab–DOX conjugate via
the same protocol as established for the full antibody, and this
species was subjected to the digest conditions. The loss of
20% of the DOX payload under these conditions, as observed
by mass spectrometry and UV-vis spectroscopy (Fig. S10 and
S11, ESI†), were used to adjust the results from the full anti-
body digestion experiment. Taking this into account, the Fab
fraction obtained from digestion was found to contain more
than 95% of the originally conjugated DOX after enzymatic
cleavage. This observation suggests that the combination of
NGMs with benzeneselenol can be used to target small mole-
cules exclusively to the Fab arms of antibodies. Additional
experimentation will be necessary to understand the chemical
and structural basis of this eﬀect.
Conclusions
ADCs oﬀer a tantalizing possibility for the development of the
next generation of therapeutics, but careful consideration
Fig. 5 Controlled synthesis of trastuzumab–DOX conjugates and localization of the payload. (a) General outline of the two-step process using
in situ disulﬁde bond modiﬁcation with NGMs followed by copper-catalysed Huisgen 1,3-dipolar cycloaddition. (b) Trastuzumab–DOX DAR series.
(M) Molecular marker. (1) Untreated antibody. (2) Reduced antibody. (3) Fragmentation control of trastuzumab prepared by treatment with 2 eq.
TCEP (4) Trastuzumab–DOX conjugate prepared with compound 6 (compare Fig. 3c, lane 3). (5) DAR 1.1: reaction on ice for 1 h followed by 90 min
click reaction. (6) DAR 2.0: as DAR 1.1 but with addition of 10 eq. benzeneselenol after 30 min and 16 h click reaction. (7) DAR 3.1: reaction at 37 °C
for 2 h followed by 90 min click reaction. (8) DAR 4.0: reaction at 37 °C for 2 h followed by 16 h click reaction. (c) Isolated yields and DAR from con-
jugation reactions, overall yield after SEC puriﬁcation. (d) CE-SDS analysis of the trastuzumab–DOX DAR series; peak area given as percentage of
total peak area. It was assumed for the calculation of correctly bridged disulphide bonds (in contrast to the population of the fragments) that the H
and L chains contained 0, the HL fragment 1, the HH fragment 2 and the HHL fragment 3 correct bridges. DAR 0 material was generated by treat-
ment of trastuzumab as outlined for DAR 3.1 material but without addition of reducing agent. (e) Binding activity of the trastuzumab DAR 1 to 4
series to HER2 compared to unmodiﬁed trastuzumab. (f ) Localization of DOX in DAR 2.0 material. (M) Molecular marker. (1) Untreated antibody. (2)
Trastuzumab bridged with compound 15. (3) Trastuzumab–DOX with a DAR of 2.0 after the click reaction. (4) DAR 2.0 material after pepsin digest.
(5) DAR 2.0 material after papain digest. (6) Control digest of unmodiﬁed trastuzumab with pepsin. (7) Control digest of pepsin digested trastuzumab
with papain.
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needs to be given to each component, including the conju-
gation method. The methods described in this paper show the
possibility for delivering high yields of homogeneous and
stable29 conjugates using site-specific reactions of native di-
sulfide bonds. It is also possible to oﬀer control over the drug
loading in a range between 0 and 4 whilst maintaining the
structure and activity of the antibody. The possibility of using
the native disulfide bonds of antibodies for bioconjugation
oﬀers potential practical advantages over antibody engineer-
ing. Moreover the possibility for targeting the Fab arms has
not, to the best of our knowledge, been described and may be
useful for spatial separation of hydrophobic payloads attached
to antibodies. The synthetic methods described herein are
practical, eﬃcient and have the potential for further modifi-
cation and optimisation depending on the antibody and
payload under investigation. For these reasons we anticipate
that the NGM platform will find considerable utility for the
development of future ADCs.
Materials and methods
General sequential bridging protocol
To trastuzumab (22.9 µM, ∼300 µL) in borate buﬀer (25 mM
sodium borate, 25 mM NaCl, 1 mM EDTA, pH 8.0) was added
TCEP (min. 5 eq., in the same buﬀer) from a 400–1000× stock
solution and the reaction incubated at 37 °C for 2 h under
mild agitation. NGMs were prepared in dry DMF (purchased
from Sigma Aldrich) as 400–1000× stock solutions and added
to reduced trastuzumab (minimum 5 eq.) to achieve a final
DMF concentration of 10%. After 1 h at 37 °C excess reagents
were removed by ultrafiltration (10 kDa MWCO).
General in situ bridging protocol with TCEP
To trastuzumab (22.9 µM, ∼300 µL) in borate buﬀer were
added NGMs (min. 5 eq. in dry DMF) from 400–1000× stock
solutions to achieve a final DMF concentration of 10%. Then
TCEP (min. 6 eq.) in borate buﬀer was added from a
400–1000× stock solution and the reaction incubated at 37 °C
for 2 h under mild agitation after which the reaction was puri-
fied by ultrafiltration (10 kDa MWCO).
General in situ bridging protocol with benzeneselenol
To trastuzumab (22.9 µM, ∼300 µL) in borate buﬀer was added
DMF to a final concentration of 12% and the mixture put on
ice. Next benzeneselenol (min. 10 eq. in dry DMF) was added
from a freshly prepared 1000× stock solution followed by
addition of NGMs (min. 10 eq. in dry DMF) from 400–1000×
stock solutions to achieve a final DMF concentration of 15%.
The reaction was kept on ice for 1 h and purified by ultrafiltra-
tion (10 kDa MWCO).
Copper-catalysed Huisgen 1,3-dipolar cycloaddition
Bridging reactions were stopped with 20 eq. of maleimide (in
dry DMF) and purified into PBS (pH 7.4) by ultrafiltration
(MWCO 10 kDa). After determination of the concentration by
UV-vis (ε280 = 215 380 cm
−1 M−1) and dilution of the antibody
to 30 µM, samples were treated with 30 eq. compound 16 in
the presence of 150 µM CuSO4, 750 µM THPTA, 5 mM amino-
guanidine HCl and 5 mM sodium ascorbate. Reactions were
incubated at 22 °C for 90 min or 16 h. ADCs were purified
by size exclusion chromatography (on a HiLoad Sephadex 75
16/60 column, GE Healthcare, equilibrated in PBS) and the
DAR calculated by UV-vis.
CE-SDS and data analysis
CE-SDS analysis was carried out on a PEREGRINE I machine
(deltaDOT). Samples were diluted to 1 mg mL−1 in SDS-MW
sample buﬀer (Proteome Lab) and heated to 65 °C for 20 min.
50 μL were transferred into sample vials and loaded into the
machine. Separations were performed in a 50 μm diameter
fused silica capillary at 22 °C. Separation length was 20.2 cm,
run time 45 min and antibody fragments detected at a wave-
length of 214 nm. The capillary was flushed with 0.1 M HCl,
water and run buﬀer before sample loading at 5 psi/16 kV.
Noise was recorded for 3 min from the run buﬀer. To verify
comparison-based fragment identification a protein sizing
standard (Beckman Coulter) was used. Data analysis was
carried out with the EVA software (version 3.1.7, deltaDOT).
Run files were loaded and analysed with the GST algorithm at
a frequency of 40 and a sensitivity of 1. GST peak search was
performed between 13 and 32 min (8000 to 20 000 scans)
based on the peak identification by mass and comparison
between unmodified, partially and fully reduced antibody
samples. Peaks corresponding to the LHHL, HHL, HH, HL, H
and L antibody species were added manually where necessary
and peak area boundaries adjusted for all signals. As the peak
area (absorbance) varies depending on the size a correction
factor between the absorbance of the full antibody and the
completely disassembled antibody (only H and L fragments)
was calculated. This factor was adjusted for the area correction
of the remaining fragments (HHL, HH, HL) depending on
their disulfide bond status, e.g. only 25% of the correction
factor was applied to the peak area of the HHL fragment as
75% of the disulfide bonds were assumed to be intact. The
normalization was established based on the samples of a
reduction series and transferred to the samples with varying
DARs. For the calculation of the correctly bridged disulfide
bonds it was assumed that the H and L fragments contained
none, the HL one, the HH two, the HHL three and the full
antibody (LHHL) four correct disulfide bonds.
Digest of DAR 2 material
A Herceptin–DOX conjugate with a DAR of 2.0 was prepared
and the pH of the sample lowered via a buﬀer exchange (into
20 mM sodium acetate, pH 3.1) by ultrafiltration (10 kDa
MWCO). Immobilized pepsin (0.15 mL) was washed 4× with
the same buﬀer and trastuzumab–DOX (0.45 mL, 3.19 mg
mL−1) was added. The mixture was incubated for 5 h at 37 °C
under constant agitation (1100 rpm). The resin was separated
from the digest using a filter column, and washed 3× with
digest buﬀer (50 mM sodium phosphate, 150 mM NaCl, 1 mM
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EDTA, pH 6.8). The digest was combined with the washes and
the volume adjusted to 0.5 mL. Next, immobilised papain
(0.5 mL, 0.25 mg mL−1) was activated with 10 mM DTT (in
digest buﬀer) under an argon atmosphere and constant agita-
tion (1100 rpm) for 1 h at 25 °C in the dark. The resin was
washed 4× with digest buﬀer (without DTT) and the 0.5 mL of
trastuzumab–DOX-Fab2 solution was added. The mixture was
incubated for 16 h at 37 °C under constant agitation (1100
rpm) in the dark. The resin was separated from the digest
using a filter column, washed 3× with PBS (pH 7.0) and the
digest combined with the washes. The buﬀer was exchanged to
PBS by ultrafiltration (10 kDa MWCO) and the volume adjusted
to 0.3 mL. In parallel, a sample of unmodified Herceptin was
processed as a control. Sample and control were analysed by
SDS-PAGE and the control by MS as well. The drug loading of
the trastuzumab–Fab–DOX was assessed by UV-vis.
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